

# B G Feagan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5704806/b-g-feagan-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

381  
papers

45,554  
citations

90  
h-index

211  
g-index

446  
ext. papers

53,711  
ext. citations

9.2  
avg, IF

7.02  
L-index

#	Paper	IF	Citations
381	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. <i>Lancet, The</i> , <b>2002</b> , 359, 1541-50	40	3264
380	Infliximab for induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2462-76	59.2	2906
379	Infliximab maintenance therapy for fistulizing Crohn's disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 876-85	59.2	1727
378	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 699-710	59.2	1465
377	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 711-21	59.2	1328
376	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1324-38	0.7	1024
375	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , <b>2012</b> , 61, 1693-700	19.2	995
374	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet, The</i> , <b>2008</b> , 371, 660-667	40	957
373	Certolizumab pegol for the treatment of Crohn's disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 228-38	59.2	935
372	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1946-1960	59.2	896
371	Ustekinumab induction and maintenance therapy in refractory Crohn's disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1519-28	59.2	813
370	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. <i>Gastroenterology</i> , <b>2004</b> , 126, 402-13	13.3	810
369	Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 292-7	59.2	782
368	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1723-1736	59.2	771
367	Natalizumab induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1912-25	59.2	764
366	A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. <i>Gastroenterology</i> , <b>2007</b> , 132, 763-86	13.3	724
365	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 621-30	6.9	724

364	Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. <i>Gastroenterology</i> , <b>2011</b> , 141, 1194-201	13.3	646
363	Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2499-507	59.2	633
362	A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. <i>Gastroenterology</i> , <b>2008</b> , 135, 1130-41	13.3	614
361	Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. <i>Gastroenterology</i> , <b>1994</b> , 106, 287-96	13.3	601
360	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1627-32	59.2	593
359	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , <b>2014</b> , 146, 85-95; quiz e14-5	13.3	572
358	A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. <i>Gastroenterology</i> , <b>2002</b> , 122, 512-30	13.3	516
357	Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1409-22	0.7	513
356	Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. <i>Gastroenterology</i> , <b>2007</b> , 132, 1672-83	13.3	505
355	Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , <b>2014</b> , 146, 96-109.e1	13.3	482
354	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , <b>2017</b> , 66, 839-851	19.2	478
353	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. <i>Gastroenterology</i> , <b>2014</b> , 147, 618-627.e3	13.3	468
352	Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 836-41	59.2	454
351	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. <i>Gastroenterology</i> , <b>2000</b> , 119, 1473-82	13.3	427
350	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1415-22	4.5	395
349	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. <i>Gastroenterology</i> , <b>2009</b> , 137, 1250-60; quiz 1520	13.3	377
348	Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 91, 635-46	6.1	349
347	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet</i> , <b>2014</b> , 384, 309-18	40	331

346	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , <b>2012</b> , 61, 535-42	19.2	328
345	C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 802-19; quiz 820	0.7	319
344	Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1218-24	6.9	301
343	Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. <i>Gastroenterology</i> , <b>1999</b> , 117, 49-57	13.3	287
342	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 1825-34	4.0	279
341	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1754-62	59.2	276
340	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , <b>2017</b> , 389, 1699-1709	4.0	271
339	Reliability and initial validation of the ulcerative colitis endoscopic index of severity. <i>Gastroenterology</i> , <b>2013</b> , 145, 987-95	13.3	254
338	Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. <i>Gastroenterology</i> , <b>1996</b> , 110, 45-51	13.3	252
337	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , <b>2015</b> , 148, 1035-1058.e3	13.3	251
336	Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. <i>Gastroenterology</i> , <b>2014</b> , 146, 681-688.e1	13.3	237
335	Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1370-7	6.9	236
334	Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. <i>Gastroenterology</i> , <b>2014</b> , 147, 1296-1307.e5	13.3	233
333	SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , <b>2015</b> , 81, 489-501.e26	5.2	231
332	An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. <i>Gastroenterology</i> , <b>2001</b> , 120, 1330-8	13.3	227
331	Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 1846-51	59.2	222
330	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 348-354.e17	6.9	217
329	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1599-1607	0.7	214

328	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , <b>2017</b> , 66, 1049-1059	19.2	203
327	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. <i>Gastroenterology</i> , <b>1999</b> , 117, 527-35	13.3	195
326	The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut</i> , <b>2015</b> , 64, 1539-45	19.2	192
325	Treat to target: a proposed new paradigm for the management of Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1042-50.e2	6.9	190
324	Inflammatory bowel disease: a Canadian burden of illness review. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 811-7		187
323	Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1030-8	0.7	174
322	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , <b>2016</b> , 150, 1568-1578	13.3	171
321	Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1470-9	4.5	168
320	Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 1079-87; quiz e85-6	6.9	167
319	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , <b>2017</b> , 153, 77-86.e6	13.3	162
318	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. <i>Gastroenterology</i> , <b>2015</b> , 148, 37-51.e1	13.3	162
317	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 188-202	6.1	158
316	The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. <i>Gastroenterology</i> , <b>2013</b> , 145, 149-157.e2	13.3	157
315	Annual cost of care for Crohn's disease: a payor perspective. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 1955-60	0.7	157
314	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 233-42	4.5	152
313	Development and validation of a histological index for UC. <i>Gut</i> , <b>2017</b> , 66, 50-58	19.2	151
312	A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 654-66	6.9	146
311	Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 325-34	6.9	145

310	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 794-802	0.7	139
309	Drug therapies and the risk of malignancy in Crohn's disease: results from the TREATRegistry. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 212-23	0.7	130
308	CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. <i>Gut</i> , <b>2004</b> , 53, 1485-93	19.2	121
307	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologicals</i> , <b>2014</b> , 42, 177-83	1.8	120
306	Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 179-94; author reply 195	0.7	117
305	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 670-678.e3	6.9	117
304	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i> , <b>2015</b> , 64, 77-83	19.2	113
303	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 229-239.e5	6.9	112
302	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 412-424	1.5	112
301	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 400-411	1.5	109
300	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 154, 1660-1671	13.3	108
299	Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. <i>Gut</i> , <b>2006</b> , 55, 1568-74	19.2	105
298	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , <b>2016</b> , 65, 1447-55	19.2	102
297	Association Between Response to Etrolizumab and Expression of Integrin $\beta$ and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 150, 477-87.e9	13.3	101
296	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 921-929	1.5	99
295	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 473-479	2.4	98
294	Therapeutic drug monitoring of biologics for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 349-58	4.5	96
293	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 671-680	18.8	94



292	A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 77-86	6.1	93
291	The effectiveness of budesonide therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1509-17	6.1	87
290	A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 58-67	2.3	86
289	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 155, 1045-1058	13.3	85
288	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 447-59	6.1	84
287	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , <b>2017</b> , 66, 588-596	19.2	82
286	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 1007-1018.e7	13.3	82
285	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. <i>Gut</i> , <b>2019</b> , 68, 1115-1126	19.2	80
284	Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 1032-41	6.1	80
283	A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2284-92	0.7	80
282	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 65-77	6.1	80
281	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	78
280	A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1126-35	6.1	78
279	Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 564-75	4.5	78
278	Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. <i>Current Gastroenterology Reports</i> , <b>2014</b> , 16, 378	5	76
277	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 35-46	1.5	76
276	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1770-6	0.7	76
275	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 674-88	6.1	76

274	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2020</b> , 158, 2123-2138.e8	13.3	75
273	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 347-357	6.1	75
272	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 23-32	1.5	75
271	Development of an index to define overall disease severity in IBD. <i>Gut</i> , <b>2018</b> , 67, 244-254	19.2	73
270	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , <b>2000</b> , 118, A874	13.3	73
269	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1200-10	6.1	71
268	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , <b>2017</b> , 152, S1308-S1309	13.3	70
267	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1879-1892	6.9	70
266	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1158-1169	1.5	70
265	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 408-418	1.5	66
264	Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1691-9	4.5	62
263	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 155, 687-695.e10	13.3	60
262	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2016</b> , CD000544	5.2	60
261	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1170-81	6.1	59
260	Briakinumab for treatment of Crohn's disease: results of a randomized trial. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1329-40	4.5	58
259	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2020</b> , 158, 537-549.e10	13.3	57
258	A phase II study of laquinimod in Crohn's disease. <i>Gut</i> , <b>2015</b> , 64, 1227-35	19.2	55
257	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 105-119	1.5	55



256	Assessment of mucosal healing in inflammatory bowel disease: review. <i>Gastrointestinal Endoscopy</i> , <b>2015</b> , 82, 246-55	5.2	55
255	Global burden of inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 2-3	18.8	53
254	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2016</b> , 4, CD000543	5.2	51
253	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 504-14	6.1	51
252	Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1151-9	4.5	50
251	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , <b>2015</b> , 64, 1765-73	19.2	49
250	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , <b>2016</b> , 65, 1119-25	19.2	49
249	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 31-40	6.1	48
248	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 621-626	1.5	47
247	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 154, 61-64.e6	13.3	46
246	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2018</b> , 16, 129-146	2.5	44
245	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 130-138.e7	6.9	44
244	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 5-23	6.1	43
243	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 819-828	18.8	42
242	Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 825-833	4	42
241	Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2031-40	4.5	42
240	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , <b>2009</b> , 58, 1354-62	19.2	42
239	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 607-16	1.5	40

238	A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1850-61	4.5	40
237	Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 2737-46	0.7	40
236	5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. <i>Clinical Gastroenterology and Hepatology</i> , <b>2004</b> , 2, 376-8	6.9	40
235	Methotrexate for induction of remission in refractory Crohn's disease. <i>The Cochrane Library</i> , <b>2014</b> , CD003459	3.5	39
234	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 50-57	1.5	39
233	Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. <i>BMJ Open</i> , <b>2016</b> , 6, e009949	3	38
232	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 157-69	6.1	37
231	Toward a personalized medicine approach to the management of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 994-1004	0.7	37
230	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 541-50	6.1	37
229	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1158-69	6.1	36
228	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2372-2384	4.0	36
227	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1058-1072	6.1	35
226	Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1997</b> , 11 Suppl 3, 98-107; discussion 107-8	6.1	35
225	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 617-28	6.1	35
224	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1280-1291	59.2	35
223	Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1678-1688	0.7	34
222	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 1708-16	4.5	34
221	Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. <i>Gastroenterology</i> , <b>1996</b> , 110, 275-83	13.3	34

220	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1353-1365	6.1	34
219	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1262-1275.e7	13.3	33
218	T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. <i>Drugs</i> , <b>2014</b> , 74, 297-311	12.1	33
217	Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1976-83	0.7	32
216	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 738-745	0.7	32
215	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 167-177	1.5	31
214	566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2012</b> , 142, S-114	13.3	31
213	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 373-84	6.1	31
212	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1197-1205	0.7	31
211	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 940-950	6.1	30
210	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , <b>2019</b> , 79, 1321-1335	12.1	30
209	Assessment of histologic disease activity in Crohn's disease: a systematic review. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 2092-103	4.5	30
208	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1407-1419.e22	6.9	29
207	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 1233-1244.e5	13.3	28
206	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 516-528	6.1	28
205	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 637-647.e13	6.9	27
204	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , <b>2019</b> , 68, 1162-1168	19.2	27
203	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 264-275	6.1	27

202	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1584-1592	0.7	26
201	The safety of vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 501-507	4.1	26
200	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1021-1042	6.1	26
199	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , <b>2017</b> , 7, e016146	3	26
198	Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 1019-1031.e7	13.3	26
197	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. <i>Gastroenterology</i> , <b>2020</b> , 158, 137-150.e1	13.3	26
196	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. <i>Drugs</i> , <b>2017</b> , 77, 363-377	12.1	25
195	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 440-449	4.5	25
194	565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). <i>Gastroenterology</i> , <b>2012</b> , 142, S-114	13.3	25
193	Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 567-71		25
192	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1658-1669	0.7	23
191	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 607-18	1.5	23
190	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 2475-82	4.5	23
189	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , <b>2018</b> , 67, 61-69	19.2	22
188	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 733-745	0.7	22
187	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2952-2961.e8	6.9	21
186	Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 292-302	6.1	20
185	Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 1006-14	1.5	20

184	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2031-2045.e11 <sup>20</sup>	6.9	19
183	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1578-1596	6.1	19
182	Alicaforsen for the treatment of inflammatory bowel disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 991-997	5.9	19
181	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , <b>2017</b> , 5, CD011256	5.2	18
180	882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. <i>Gastroenterology</i> , <b>2018</b> , 154, S-1360-S-1361	13.3	18
179	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1714-1729.e3	6.9	18
178	DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, S42-S43	1.5	18
177	Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. <i>BioDrugs</i> , <b>2020</b> , 34, 713-721	7.9	18
176	Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 987-97	4.1	17
175	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2019</b> ,	13.3	17
174	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 994-1007	4.5	17
173	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101604	2.5	16
172	Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologicals</i> , <b>2012</b> , 40, 517-27	1.8	16
171	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1120-1129	1.5	16
170	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	16
169	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 88, 360-369.e2	5.2	15
168	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1188-1194	6.1	14
167	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1086-1093	6.1	13



166	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 649-660	5.9	13
165	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 246-255	1.5	13
164	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 553-564	6.1	13
163	Vedolizumab for the treatment of moderately to severely active ulcerative colitis. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 412-23	5.8	12
162	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , <b>2017</b> , 9, CD011572	5.2	12
161	P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease Additional Results from GEMINI 1 and 2. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, S80	4.5	12
160	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2010</b> , 138, S-167-S-168	13.3	12
159	Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	12
158	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4491-4518	4.1	12
157	Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1047-1056	4.5	11
156	Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. <i>Drug Safety</i> , <b>2019</b> , 42, 617-632	5.1	11
155	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101602	2.5	11
154	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1233-1246	6.1	11
153	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1100-1111	6.1	11
152	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 435-445	6.1	11
151	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD000544	5.2	11
150	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 63-70	18.8	11
149	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1401-1409	6.1	10



148	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 883-895	1.5	10
147	OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn's disease (CD). <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S016-S017	1.5	10
146	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , <b>2021</b> , 160, 2291-2302	13.3	10
145	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1047-1066	6.1	10
144	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1201-1216	1.5	9
143	Ozanimod Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, e17	59.2	9
142	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 424-431.e7	6.9	9
141	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD000543	5.2	9
140	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2500-2509.e1	6.9	8
139	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2519-2528	4	8
138	Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn's Disease (CD). <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, S457-S458	0.7	8
137	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1121-1132.e2	6.9	8
136	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	8
135	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. <i>Lancet, The</i> , <b>2022</b> , 399, 2015-2030	40	8
134	The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 661-677	4.4	7
133	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , <b>2017</b> , 152, S602	13.3	7
132	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	7
131	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1008-1016	6.1	7

130	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1760-1768.e1	6.9	7
129	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 843-851	4.5	7
128	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 114-126	6.1	7
127	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 885-894	0.7	6
126	OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S024-S025	1.5	6
125	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2555-2563	4	6
124	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 304-313	4.5	6
123	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 873-886	6.1	6
122	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	6
121	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2139-2141.e2	6.9	6
120	Portal Hypertensive Bleeding <b>2010</b> , 562-602		6
119	P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn's disease in the STEPSTONE trial. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S450-S450	1.5	5
118	1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial. <i>Gastroenterology</i> , <b>2014</b> , 146, S-187	13.3	5
117	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	5
116	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet, The</i> , <b>2022</b> , 399, 2031-2046	4.0	5
115	Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn's Disease: A Gemini 2 Post hoc Analysis. <i>Gastroenterology</i> , <b>2017</b> , 152, S597	13.3	4
114	Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 793-801	5.5	4
113	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. <i>Applied Health Economics and Health Policy</i> , <b>2018</b> , 16, 279-288	3.4	4

112	The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1737-43	4.5	4
111	P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, S248	1.5	4
110	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn’s Disease. <i>Gastroenterology</i> , <b>2017</b> , 152, S1310	13.3	4
109	Infliximab in the treatment of Crohn’s disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2000</b> , 14 Suppl C, 6C		4
108	OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. <i>Journal of Crohns and Colitis</i> , <b>2022</b> , 16, i042-i043	1.5	4
107	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn’s Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, S371	0.7	4
106	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1574-1582	6.1	4
105	A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. <i>Saudi Journal of Gastroenterology</i> , <b>2015</b> , 21, 185-97	3	4
104	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn’s Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 515-523	4.5	4
103	International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease. <i>Gut</i> , <b>2021</b> ,	19.2	4
102	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	4
101	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , <b>2021</b> , 81, 333-347.	2.1	4
100	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	4
99	Vedolizumab for the treatment of inflammatory bowel diseases. <i>Clinical Investigation</i> , <b>2015</b> , 5, 247-255		3
98	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <i>Current Treatment Options in Gastroenterology</i> , <b>2014</b> , 12, 76-89	2.5	3
97	P-26 Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, S24-S25	4.5	3
96	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn’s Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	3
95	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , <b>2020</b> , 159, 2013-2018.e7	13.3	3

94	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , <b>2016</b> , 34 Suppl 1, 67-73	3.2	3
93	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 784-793	6.1	3
92	Ogilvie's Syndrome 303-309		3
91	Clostridium Difficile Associated Disease: Diagnosis and Treatment <b>2010</b> , 335-354		3
90	Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2016</b> , 150, S409	13.3	2
89	OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i025-i026	1.5	2
88	Update on Tofacitinib for Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2016</b> , 12, 572-574		2
87	Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 244-246	0.7	2
86	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
85	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2155-2164	4.5	2
84	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , <b>2018</b> , 459, 50-54	2.5	2
83	Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. <i>Scientific Reports</i> , <b>2021</b> , 11, 18243	4.9	2
82	Development of Anti-fibrotic Therapy in Strictureing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. <i>Physiological Reviews</i> , <b>2021</b> ,	47.9	2
81	Liver Transplantation: Prevention and Treatment of Rejection <b>2010</b> , 685-723		2
80	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1108-1117	6.1	2
79	Combination therapy for the treatment of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1429-42	5.4	1
78	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2020</b> , 5, CD012877	5.2	1
77	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	1

76	New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 2948-57	4.5	1
75	Hepatic Encephalopathy: Treatment <b>2010</b> , 636-649		1
74	Ulcer Disease and Helicobacter pylori Infection: Etiology and Treatment <b>2010</b> , 102-138		1
73	Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, S40-S41	4.5	1
72	P-0068: Natalizumab reduces the rate of hospitalization in moderate to severe Crohn's Patients: Evidence from the Clinical Trial Program. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, S27	4.5	1
71	Colorectal Cancer in Ulcerative Colitis: Surveillance 247-253		1
70	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2014</b> , 10, 478-489	0.7	1
69	Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn's disease: Meta-analysis of Randomised controlled trials. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	1
68	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2021</b> ,	0.7	1
67	The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review. <i>Saudi Journal of Gastroenterology</i> , <b>2019</b> , 25, 152-158	3	1
66	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1442-1453	6.1	1
65	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , <b>2020</b> , 18, 442-461	2.5	1
64	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 364-374	6.1	1
63	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 639-646	4.5	1
62	Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1513-1524	4.5	1
61	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
60	Clostridium Difficile Disease 285-301		1
59	Non-Alcoholic Fatty Liver Disease 393-403		1

58	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis	487-503		1
57	Fulminant Hepatic Failure	527-543		1
56	Ulcer Disease and Helicobacter Pylori	83-116		1
55	Non-Variceal Gastrointestinal Hemorrhage	139-159		1
54	Celiac Disease: Diagnosis, Treatment and Prognosis	2010, 200-210		1
53	Prevention and Treatment of Travelers' Diarrhea	2010, 324-334		1
52	Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders	2010, 78-92		1
51	Management of HBV Infection and Liver Transplantation	2010, 748-761		1
50	P-25 Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial. <i>Inflammatory Bowel Diseases</i> ,	2012, 18, S23-S24	4.5	o
49	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 $\beta$ stabiliser, for treatment of ulcerative colitis.. <i>Alimentary Pharmacology and Therapeutics</i> ,	2022, 55, 401	6.1	o
48	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> ,	2020, 18, 15	2.5	o
47	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> ,	2021, 1	4	o
46	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> ,	2019, 17, 1637-1640	6.9	o
45	Liver Biopsy	2010, 762-770		o
44	Drug Induced Liver Disease: Mechanisms and Diagnosis	2010, 771-786		o
43	The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC)	2019, 25-42		
42	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> ,	2019, 25, 472-478	4.5	
41	Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> ,	2014, 40, 121-2	6.1	



40	P-24 The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECISE 2 Trial. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, S23	4.5
39	P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i596-i597	1.5
38	Anti-adhesion strategies for inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , <b>2010</b> , 6, 372-4	0.7
37	Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2017</b> , 13, 745-747	0.7
36	Review of the Landmark VARSITY Trial. <i>Gastroenterology and Hepatology</i> , <b>2021</b> , 17, 330-332	0.7
35	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , <b>2021</b> , 19, 608	2.5
34	Obesity Management: Considerations for the Gastroenterologist <b>2010</b> , 415-434	
33	Pouchitis after Restorative Proctocolectomy <b>2010</b> , 248-256	
32	Liver Transplantation: Prevention and Treatment of Infection <b>2010</b> , 724-739	
31	Hepatitis B: Prognosis and Treatment <b>2010</b> , 448-464	
30	Drug-Induced Diarrhea <b>2010</b> , 267-279	
29	Non-Histological Assessment of Liver Fibrosis <b>2010</b> , 554-561	
28	Metabolic Bone Disease in Gastrointestinal Disorders <b>2010</b> , 280-300	
27	Management of HCV Infection and Liver Transplantation <b>2010</b> , 740-747	
26	Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis <b>2010</b> , 619-635	
25	Fulminant Hepatic Failure: Treatment <b>2010</b> , 661-684	
24	Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity <b>2010</b> , 139-164	
23	Functional Dyspepsia <b>2010</b> , 190-199	

- 22 Colorectal Cancer: Population Screening and Surveillance **2010**, 311-323
- 21 Ogilvie's Syndrome **2010**, 377-384
- 20 Colorectal Cancer in Ulcerative Colitis: Surveillance **2010**, 301-310
- 19 Hepatic Outflow Syndromes and Splanchnic Venous Thrombosis **2010**, 603-618
- 18 Microscopic Colitis: Collagenous and Lymphocytic Colitis **2010**, 257-266
- 17 Gallstone Disease **2010**, 385-395
- 16 Acute Non-Variceal Gastrointestinal Hemorrhage: Treatment **2010**, 165-189
- 15 Non-Alcoholic Fatty Liver Disease **2010**, 475-483
- 14 Barrett's Esophagus **2010**, 62-77
- 13 P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis. *Journal of Crohns and Colitis*, **2020**, 14, S231-S231 1.5
- 12 A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. *Gastroenterology*, **2021**, 161, 778-784 13.3
- 11 Metabolic Bone Disease in Gastrointestinal Disorders 231-246
- 10 Gallstone Disease 311-320
- 9 Hemochromatosis and Wilson Disease 405-413
- 8 Barrett's Esophagus 55-68
- 7 Liver Transplantation: Prevention and Treatment of Rejection 545-571
- 6 Liver Transplantation: Prevention and Treatment of Infection 573-586
- 5 Management of Hepatitis B and C After Liver Transplantation 587-601

4 Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders 69-81

3 Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal Toxicity 117-138

2 Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 957-958 6.1

1 Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. *Gastroenterology and Hepatology*, **2022**, 18, 14-27 0.7